Cai Jing Wang·2026-02-10 08:33Core Viewpoint - Recently, Lizhu Group released an investor research record detailing the progress of its innovative drug, Lakanqita monoclonal antibody, in the immunology field and vaccine development [1] Immunology Field - Lakanqita monoclonal antibody is the company's flagship product, currently undergoing clinical research for moderate to severe psoriasis and ankylosing spondylitis [1] - The psoriasis indication has been submitted for market approval and included in the CDE priority review, with the earliest approval expected by the end of this year [1] - The ankylosing spondylitis indication is expected to be submitted for market approval in Q2 2026 [1] - Phase III clinical research shows a PASI 100 response rate of 49.5% for the Lakanqita monoclonal antibody group, significantly better than the 40.2% response rate for Secukinumab [1] - The company has initiated overseas collaboration discussions to explore the development of new indications in the future [1] Vaccine Development - The company is advancing the development of an inactivated influenza vaccine and recombinant human follicle-stimulating hormone injection [1] - The quadrivalent recombinant protein influenza vaccine is expected to enter Phase II clinical trials in the first half of 2026 [1] - The recombinant human follicle-stimulating hormone injection is anticipated to receive market approval within 2026 [1] - The company emphasizes the continued use of AI technology to enhance research and development efficiency, shorten development cycles, and further strengthen market competitiveness [1]